NZ752916A - Methods of treating uterine fibroids and endometriosis - Google Patents

Methods of treating uterine fibroids and endometriosis

Info

Publication number
NZ752916A
NZ752916A NZ752916A NZ75291617A NZ752916A NZ 752916 A NZ752916 A NZ 752916A NZ 752916 A NZ752916 A NZ 752916A NZ 75291617 A NZ75291617 A NZ 75291617A NZ 752916 A NZ752916 A NZ 752916A
Authority
NZ
New Zealand
Prior art keywords
subject
methods
endometriosis
reducing
uterine fibroids
Prior art date
Application number
NZ752916A
Other languages
English (en)
Inventor
Brendan Mark Johnson
Lynn Seely
Mudd, Jr
Susan Wollowitz
Mark Hibberd
Masataka Tanimoto
Vijaykumar Reddy Rajasekhar
Mayukh Vasant Sukhatme
Original Assignee
Takeda Pharmaceuticals Co
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ752916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co, Myovant Sciences Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of NZ752916A publication Critical patent/NZ752916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
NZ752916A 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis NZ752916A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
NZ752916A true NZ752916A (en) 2022-09-30

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ752916A NZ752916A (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Country Status (24)

Country Link
US (4) US11033551B2 (enExample)
EP (2) EP3518933B2 (enExample)
JP (1) JP7043503B2 (enExample)
CN (1) CN110312512B (enExample)
AU (2) AU2017336363B2 (enExample)
BR (1) BR112019006227A2 (enExample)
CA (1) CA3038879A1 (enExample)
CY (1) CY1125254T1 (enExample)
DK (1) DK3518933T4 (enExample)
ES (2) ES2912929T5 (enExample)
FI (1) FI3518933T4 (enExample)
HR (1) HRP20220708T4 (enExample)
HU (2) HUE059101T2 (enExample)
IL (2) IL300580B2 (enExample)
LT (1) LT3518933T (enExample)
MD (1) MD3518933T4 (enExample)
MX (1) MX2019003726A (enExample)
NZ (1) NZ752916A (enExample)
PL (2) PL4094766T3 (enExample)
PT (1) PT3518933T (enExample)
RS (1) RS63300B2 (enExample)
SI (1) SI3518933T2 (enExample)
SM (1) SMT202200254T1 (enExample)
WO (1) WO2018060501A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
DK3634419T3 (da) 2017-06-05 2025-03-31 Kissei Pharmaceutical Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
MA54058A (fr) * 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CA3172074A1 (en) * 2020-02-19 2021-08-26 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US528409A (en) 1894-10-30 Denis ahern
US402150A (en) 1889-04-30 Broadcast seed-sower
US402055A (en) 1889-04-23 Water-motor
US492839A (en) 1893-03-07 Key for brake-shoes
US402034A (en) 1889-04-23 Dumping-wagon
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
EP1646389B1 (en) 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
EP4223298A3 (en) * 2013-03-15 2023-08-16 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
WO2017040841A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
IL300580A (en) 2023-04-01
MX2019003726A (es) 2019-09-26
US20220370462A1 (en) 2022-11-24
BR112019006227A2 (pt) 2019-06-18
RS63300B2 (sr) 2025-05-30
EP3518933B1 (en) 2022-03-16
AU2022241582A1 (en) 2022-10-27
EP4094766B1 (en) 2025-04-02
US20190262346A1 (en) 2019-08-29
SI3518933T1 (sl) 2022-06-30
EP3518933A2 (en) 2019-08-07
AU2022241582C1 (en) 2024-11-28
US20210401841A1 (en) 2021-12-30
IL300580B1 (en) 2025-07-01
AU2022241582B2 (en) 2024-06-13
US11793812B2 (en) 2023-10-24
HRP20220708T4 (hr) 2025-04-25
WO2018060501A3 (en) 2018-05-11
JP7043503B2 (ja) 2022-03-29
AU2017336363A1 (en) 2019-05-16
US11033551B2 (en) 2021-06-15
HUE059101T2 (hu) 2022-10-28
SMT202200254T1 (it) 2022-07-21
JP2019529575A (ja) 2019-10-17
US20240165118A1 (en) 2024-05-23
IL265700B2 (en) 2023-07-01
IL300580B2 (en) 2025-11-01
CA3038879A1 (en) 2018-04-05
CN110312512A (zh) 2019-10-08
PL3518933T3 (pl) 2022-06-20
PL4094766T3 (pl) 2025-07-28
HRP20220708T1 (hr) 2022-07-22
US11957684B2 (en) 2024-04-16
CY1125254T1 (el) 2024-02-16
DK3518933T4 (da) 2025-04-22
ES2912929T5 (en) 2025-05-09
PT3518933T (pt) 2022-05-10
IL265700A (en) 2019-05-30
MD3518933T2 (ro) 2022-07-31
LT3518933T (lt) 2022-06-10
ES2912929T3 (es) 2022-05-30
CN110312512B (zh) 2023-05-09
WO2018060501A2 (en) 2018-04-05
FI3518933T4 (fi) 2025-05-14
RS63300B1 (sr) 2022-07-29
IL265700B1 (en) 2023-03-01
ES3018413T3 (es) 2025-05-16
EP4094766A1 (en) 2022-11-30
AU2017336363B2 (en) 2022-08-04
DK3518933T3 (da) 2022-05-30
EP3518933B2 (en) 2025-02-26
MD3518933T4 (ro) 2025-10-31
HUE072130T2 (hu) 2025-10-28
PL3518933T5 (pl) 2025-05-05
SI3518933T2 (sl) 2025-05-30

Similar Documents

Publication Publication Date Title
WO2018060501A3 (en) Methods of treating uterine fibroids and endometriosis
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2023001468A (es) Tratamiento de cancer de prostata.
EA201791361A1 (ru) Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий
AU2010286569A1 (en) Compounds and compositions as protein kinase inhibitors
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
TW200736249A (en) Aminopyrimidines useful as kinase inhibitors
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
ATE534632T1 (de) Thiazole, imidazole und pyrazole als proteinkinasehemmer
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EP4509173A3 (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
MX2024007444A (es) Inhibidores de cinasa met.
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
MX389041B (es) Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
EA201990857A1 (ru) Способы лечения миомы матки и эндометриоза
MY188267A (en) Progesterone receptor antagonist dosage form
MA46362B1 (fr) Méthodes de traitement des fibromes utérins et de l'endométriose
EA201990762A1 (ru) Способы лечения женского бесплодия
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2025 BY COMPUTER PACKAGES INC

Effective date: 20240830

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2026 BY COMPUTER PACKAGES INC

Effective date: 20250830

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20260326

Owner name: SUMITOMO PHARMA CO., LTD, JP

Effective date: 20260326